A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets

NCT ID: NCT03151720

Last Updated: 2017-08-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-01
• Study Completion Date: 2017-07-08

Brief Summary

The purpose of this study is to establish the relative bioavailability of Xisimin (loratadine) compared to Clarityne in healthy participants receiving a single dose of 10 milligram (mg) under fasting condition as part of Cohort 1 and under fed condition as part of Cohort 2.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Cohort 1: Sequence 1 (ABAB)

Participants will receive 10 milligram (mg) loratadine (1\*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1\*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.

Group Type: EXPERIMENTAL

loratadine (Xisimin [Test Treatment])

Intervention Type: DRUG

Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

loratadine (Clarityne [Reference Treatment])

Intervention Type: DRUG

Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Cohort 1: Sequence 2 (BABA)

Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.

Group Type: EXPERIMENTAL

loratadine (Xisimin [Test Treatment])

Intervention Type: DRUG

Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

loratadine (Clarityne [Reference Treatment])

Intervention Type: DRUG

Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Cohort 2: Sequence 1 (ABAB)

Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.

Group Type: EXPERIMENTAL

loratadine (Xisimin [Test Treatment])

Intervention Type: DRUG

Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

loratadine (Clarityne [Reference Treatment])

Intervention Type: DRUG

Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Cohort 2: Sequence 1 (BABA)

Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.

Group Type: EXPERIMENTAL

loratadine (Xisimin [Test Treatment])

Intervention Type: DRUG

Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

loratadine (Clarityne [Reference Treatment])

Intervention Type: DRUG

Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Interventions

loratadine (Xisimin [Test Treatment])

Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention Type: DRUG

loratadine (Clarityne [Reference Treatment])

Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Intervention Type: DRUG

Other Intervention Names

JNJ-1754415-AAA

Eligibility Criteria

Inclusion Criteria

• Body mass index (BMI, weight [kilogram]/height^2 [meter^2]) between 19.0 and 26.0 kg/m2 (kilogram per meter square) (inclusive); body weight of male participants not less than 50 kilogram (kg) and body weight of female participants not less than 45 kg
• If a woman, must be surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (example, prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry, throughout the study, and for 1 month after the last dose of study drug
• If a woman, must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1 of each treatment period
• If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 2 months after receiving the last dose of study drug
• If a man who is sexually active with a woman of childbearing potential and has not had a vasectomy, must agree to use an adequate contraception method as deemed appropriate by the investigator (example, vasectomy, double-barrier, partner using effective contraception) and to not donate sperm during the study and for 3 months after receiving the last dose of study drug. Must agree to continue using an appropriate method of birth control during the study and for 3 month after the last dose of study drug

Exclusion Criteria

• History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), gastrointestinal disease, lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
• Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or on Day -1 of each treatment period as deemed appropriate by the investigator
• Clinically significant abnormal physical examination, vital signs or 12 lead electrocardiogram (ECG) at screening or on Day -1 of each treatment period as deemed appropriate by the investigator
• Clinically significant abnormal chest radiography at screening as deemed appropriate by the investigator
• Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for oral contraceptives and paracetamol within 14 days before the first dose of the study drug is scheduled

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xian-Janssen Pharmaceutical Ltd., China Clinical Trial

Role: STUDY_DIRECTOR

Xian-Janssen Pharmaceutical Ltd.

Locations

Tri-Service Genaral Hospital

Taipei, , Taiwan

Countries

Taiwan

Other Identifiers

1754415ALY1001

Identifier Type: OTHER

Identifier Source: secondary_id

CR108321

Identifier Type: -

Identifier Source: org_study_id